These observations, taken together with studies with cultured endothelial cells, indicate that dasatinib promoted endothelial permeability via the Rho‐ROCK‐MLC pathway and ROCK inhibitor attenuated the endothelial dysfunction. The gene discussed is MLC1; the disease is endothelial dysfunction.